LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Dellegra (fexofenadine + pseudoephedrine), the two companies said on August 4. The financial terms of the deal were undisclosed. The Japan arm of French giant Sanofi…
To read the full story
Related Article
- LTL Pharma Looks to Acquire More Off-Patent Brands with Dellegra as a Catalyst
September 24, 2020
- LTL Pharma to License Dellegra AG to Nichi-Iko, Eyeing December Rollout
September 3, 2020
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





